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Abstract: Marine algae contain various bromophenols that have been shown to possess a variety of
biological activities, including antiradical, antimicrobial, anticancer, antidiabetic, anti-inflammatory
effects, and so on. Here, we briefly review the recent progress of these marine algae biomaterials
and their derivatives from 2011 to 2020, with respect to structure, bioactivities, and their potential
application as pharmaceuticals.
Keywords: bromophenols; derivatives; marine algae; bioactivity
1. Introduction
Marine algae are exceptionally rich sources of structurally diverse bioactive compounds, and
a number of novel compounds exhibiting interesting biological activities have been isolated from
marine algae [1,2]. Bromophenols (BPs) are one group of such compounds isolated from marine
algae. Structurally, BPs include one or more benzene rings and contain different numbers of hydroxyl,
bromine, or other groups. In 1967, the first two BPs were isolated from the red algae Rhodomela larix [3].
Over the past few decades, a great number of BPs were isolated from various marine algae species
including red algae [4–9], green algae [10–14], and brown algae [15–19]. Some BPs are also found
in other marine organisms such as sponges [18,20–24], ascidians [25–27], mussels [28], polychaetes [29],
and marine proteobacteria [30]. However, BPs from microalgae have not yet been reported. It is
generally believed that the ecological function of marine BPs is chemical defense and as deterrents for
other marine organisms [31].
BPs are common marine secondary metabolites, and biosynthesized in the presence of
bromoperoxidases, bromase, laccase, hydrogen peroxide, and bromide. The biosynthetic pathways
of these natural BPs are not very clear, with only a few reports illustrating genetic, molecular basis,
and bromase effects for the production of BPs in marine organisms [30,32–34]. Lindqvist et al. [35]
found an apparent correlation between the concentration of pigments in Ceramium tenuicorne and
the levels of BPs and speculated that this was linked to photosynthetic activity via bromoperoxidase
working as a scavenger for the formed hydrogen peroxide. This could be supported by the bromination
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of 2,4,6-tribromophenol in isolated clonal material of C. tenuicorne [36]. Another study of the
Chinese marine red alga Symphyocladia latiuscula revealed a plausible and convergent biosynthetic
pathway of some BPs with a long, branched chain. These kinds of BPs could be regarded
as adducts between aconitates and intermediate quinone methide, which were generated from
2,3,6-tribromo-4,5-dihydroxybenzyl alcohol, and aconitic acid was the dehydration product of citric
acid. After the intermediate was formed, BPs were produced through reactions such as decarboxylation
and oxidation [37].
Over the years, marine BPs have attracted much attention in the field of food and pharmaceutical
agents due to their beneficial biological activities [31]. In our previous review, we have summarized the
diverse biological activities, such as antimicrobial, anticancer, antioxidant, and antidiabetic, of marine
BPs from seaweeds reported before 2011 [38]. In the last decade, novel BPs and more of their bioactivities
have been reported. Moreover, it is worth noting that more studies have focused on the design and
synthesis of novel functional derivatives of BPs [39–46], as well as on the illustration of the mechanisms
underlying their bioactivity, than only focusing on the isolation and testing the biological activity of
BPs found in natural products. Therefore, it is necessary to report these new findings, and so in the
present review, we mainly focus on the biological activities of newly discovered BPs from marine algae
and also on some of BPs’ representative derivatives synthesized in the last ten years. Recently, BPs have
also been treated briefly in other reviews [47–49].
2. Bioactivities of BPs and Potential Use in Medicine
2.1. Anticancer Activity
In the past decade a lot of BPs with anticancer activities have been isolated from marine sources,
and some of them possess potential to be developed as novel anticancer agents. For example,
BPs isolated from the marine algae Leathesia nana and Rhodomela confervoides (1.1 (also 2.8, 4.7, and 7.3.3)
and 1.2 (also 2.7 and Scheme 1), respectively) are good candidates as anticancer agents via inhibition of
cell growth against various human cancer cell lines and inhibition against the tumor angiogenesis.
BP 1.1 was reported to be cytotoxic to human cervical carcinoma cell line HeLa, human colorectal
carcinoma cell line HCT-116, human colorectal carcinoma cell line HCT-8, human hepatocellular
carcinoma cell line SMMC-7721, human lung adenocarcinoma epithelial cell line A549, and especially to
human myelogenous leukemia cell line K562 (Table 1). Compound 1.1 was able to induce mitochondrial
apoptosis in cancer cells and inhibit the activity of topoisomerase [50]. However, it seems that BP
1.1 interacts with the DNA molecules rather than directly binding to the topoisomerases [50,51].
Compound 1.1 displayed potent anti-angiogenic activity via disturbing the VEGF signaling [52].
This compound could decrease the migration and cord formation of human umbilical vein endothelial
cell line HUVEC and inhibit the subintestinal vessel in zebrafish embryos. Compound 1.2 was able to
inhibit the growth of several cancer cells in vitro, including that of HeLa, human colon adenocarcinoma
cell line RKO, HCT-116, human glioma cell line U87, and especially of human hepatoma cell line
Bel7402 (IC50 = 8.7 µg/mL, Table 1). Recent research showed that the in vitro cytotoxic mechanisms
of 1.2 were related to the modulation of β1-integrin/FAK signaling and subsequent inhibition of the
proliferation, migration, and invasion of hepatocellular carcinoma cells [53]. Moreover, compound
1.2 had anti-angiogenic properties (Table 1) via inhibiting tyrosine kinase and endothelial nitric oxide
synthase [8], suggesting anticancer activity as well [53]. Another BP 1.3 (Scheme 1), a dibromotyrosine
derivative from the Pseudoceratina sp. sponge, also exhibited potent pro-apoptotic effects (Table 1)
through targeting the IKK/NFκB signaling pathway as well as inhibiting the activity of topoisomerase
II [54].
In order to increase the anticancer potency, synthetic modifications are applied to several marine
BPs. Some synthetic derivatives containing an indolin-2-one moiety have been designed, synthesized,
and evaluated for their cytotoxic activity. BPs 1.4–1.8 (Scheme 1) containing the indolin-2-one moiety
displayed potent cytotoxicity to A549, Bel7402, human hepatocellular carcinoma cell line HepG2,
Mar. Drugs 2020, 18, 411 3 of 32
HeLa, and HCT-116 cancer cell lines (IC50 values of these BP derivatives against these cancer cell lines
are shown in Table 1) [55]. BP 1.9 (Scheme 1) could inhibit the proliferation of many human cancer
cell lines, including A549, HepG2, Bel7402, HCT-116 and human clonal colon adenocarcinoma cell
line Caco2, with IC50 values shown in Table 1. Furthermore, BP 1.9 has been shown to induce cell
cycle arrest at the G0/G1 phase of A549 cells and stimulate reactive oxygen species (ROS)-mediated
apoptosis in A549 cells [56].
Another BP derivative, 1.10 (Scheme 1) containing the indole-2-one moiety with a similar chemical
structure as 1.9, effectively inhibited the proliferation of human A549 lung cancer cells, with an IC50
value of 4.29 ± 0.79 µM. BP 1.10 could block A549 cells at the G0/G1 phase and induce apoptosis [57].
Regarding the molecular mechanisms of this cytotoxic activity, BP 1.10 has been reported to increase the
production of cellular ROS and inactivate the PI3K/Akt pathway while activating the mitogen-activated
protein kinase (MAPK) pathway [57]. BP 1.11 (Scheme 1), with a similar chemical structure of 1.9 and
1.10, also showed similar cytotoxic activities against A549 cells through inhibiting the proliferation,
arresting G0/G1 cell phase, inducing apoptosis and autophagy via deactivating PI3K/Akt/mTOR,
and activating MAPK signaling pathways [58].
Several BP thiosemicarbazone hybrid derivatives with anticancer effects were synthesized in recent
years. A novel synthesized BP thiosemicarbazone hybrid 1.12 (Scheme 1) could effectively inhibit
human ovarian cancer cell line SK-OV-3, Bel7402, and HepG2 proliferation, with IC50 values shown
in Table 1, and the compound could induce apoptosis and cell cycle arrest in SK-OV-3 cell line.
BP 1.12 also exhibited tumor growth inhibition in an in vivo SK-OV-3 cell xenograft mice model.
Further investigation showed that this compound exerted its cytotoxic activity through multiple
anticancer mechanisms, such as selective inhibition of poly (ADP-ribose) polymerase-1 (PARP-1) activity,
DNA repair alterations, inhibition of PARylation, as well as the production of cytotoxic ROS [59].
In addition, BP 1.12 displayed good pharmacokinetic characteristics and nontoxic behavior [59].
This observation indicated that compound 1.12 may serve as a lead compound for the development of
new anticancer drugs. Another BP thiosemicarbazone hybrid 1.13 (Scheme 1) also inhibited PARP-1
(IC50 = 58.3 nM) and cell proliferation, induced cells apoptosis, and arrested cell cycle in human breast
cancer cell line HCC-1937 [60].
Although the above BPs showed great cytotoxicity, their selectivity is unclear—that is, their effects
on normal cells still need to be investigated. In addition, the mechanisms of their anticancer effects
have not been fully clarified and their structure-activity (SAR) relationship also needs to be explained
further. All this is important in order to find novel and safe compounds as anticancer candidates.Mar. Drugs 2020, 18, x FOR PEER REVIEW 4 of 38 
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Table 1. Anticancer activity and names of compounds in Scheme 1.
No. IC50 (µM) and Cells Names
1.1 13.9 (K562), µg/mL Bis(2,3-dibromo-4,5-dihydroxybenzyl)ether [50]
1.2 17.63 (Hela), 11.37 (RKO), 10.58 (HCT-116), 23.69 (U87), 8.7 (Bel7402),
µg/mL, 3.6 (Human umbilical vein endothelial cells) Bis-(2,3-dibromo-4,5-dihydroxy-phenyl)-methane [53]
1.3 1.4 (K562), 4.8 (HeLa), 1.9 (MCF-7), 5.5 (MDB-MB-231), µg/mL (1′R,5′S,6′S)-2-(3′,5′-dibromo-1′,6′-dihydroxy-4′-oxocyclohex-2′-enyl)acetonitrile [54]
1.4 6.6 ± 0.82 (A549), 9.2 ± 0.84 (Bel7402), 13.2 ± 2.42 (HepG2), 9.1 ± 0.13(HCT-116), 7.4 ± 0.22 (HeLa), µg/mL (E)-3-(3-bromo-4,5-dimethoxybenzylidene-N-(4-bromophenyl)-2-oxoindoline-5-sulfonamide [55]
1.5 14.4 ± 1.86 (A549), 12.3 ± 0.23 (Bel7402), 14.3 ± 0.86 (HepG2), 9.8 ± 0.55(HCT-116), 8.3 ± 0.67 (HeLa), µg/mL (E)-N-(4-bromophenyl)-3-(2,3-dibromo-4,5-dimethoxybenzylidene)-2-oxoindoline-5-sulfonamide [55]
1.6 10.1 ± 0.72 (A549), 9.7 ± 2.35 (Bel7402), 11.2 ± 1.26 (HepG2), 8.6 ± 0.26(HCT-116), 18 ± 0.13 (HeLa), µg/mL (E)-3-(2,3-dibromo-4,5-dimethoxybenzylidene)-5-(morpholinosulfonyl)indolin-2-one [55]
1.7 12.5 ± 0.19 (A549), 7.9 ± 0.26 (Bel7402), 25 ± 0.18 (HepG2), 6.1 ± 0.23(HCT-116), 8.6 ± 0.14 (HeLa), µg/mL (E)-N-(adamantan-1-yl)-3-(3-bromo-4,5-dimethoxybenzylidene)-2-oxoindoline-5-sulfonamide [55]
1.8 12.5 ± 0.45 (A549), 12.5 ± 0.39 (Bel7402), 14.2 ± 0.77 (HepG2), 8.2 ± 0.54(HCT-116), 9.3 ± 0.47 (HeLa), µg/mL (E)-N-(adamantan-1-yl)-3-(2,3-dibromo-4,5-dimethoxybenzylidene)-2-oxoindoline-5-sulfonamide [55]
1.9 3.15 ± 0.43 (A549), 6.10 ± 0.78 (HepG2), 4.42 ± 0.72 (Bel7402), 5.74 ± 0.26(HCT-116), 4.23 ± 0.32 (Caco2), µg/mL (E)-3-(3-bromo-5-methoxy-4-(2-(piperidin-1-yl)ethoxy)benzylidene)-N-(4-bromophenyl)-2-oxoindoline-5-sulfonamide [56]
1.10 4.29 ± 0.79 (A549) 3-(4-(3-([1,4′-bipiperidin]-1′-yl)propoxy)-3-bromo-5-methoxybenzylidene)-N-(4-bromophenyl)-2-oxoindoline-5-sulfonamide [57]
1.11 4.78 ± 0.56 (A549), 9.99 ± 1.81 (95D), 6.14 ± 0.60 (NCI-H460), µg/mL 3-(3-bromo-5-methoxy-4-(3-(piperidin-1-yl)propoxy)benzylidene)-N-(4-bromophenyl)-2-oxoindoline-5-sulfonamide [58]
1.12 2.39 ± 0.43 (SK-OV-3), 5.45 ± 1.03 (Bel7402), 4.60 ± 0.38 (HepG2) 2-(2,3-dibromo-4,5-dimethoxybenzylidene)hydrazine-1-carbo-thioamide [59]
1.13 1.89 ± 0.22 (HCC-1937) (E)-4-(2-(2,3-dibromo-4,5-dimethoxybenzylidene)hydrazine-1-carbothioamido)benzoate [60]
Notes: unit for IC50 is µM, unless labeled as µg/mL.
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2.2. Antidiabetic and Anti-Obesity Activity
Marine algae have been used for a long time as a remedy for diabetes in folk medicine in China [61],
and BPs obtained from marine algae have been reported to be potential hypoglycemic agents,
acting as inhibitors against metabolic enzymes, mainly including tyrosine phosphatase 1B (PTP1B),
α-glucosidase, α-amylase, and aldose reductase (AR). PTP1B is a negative regulator of insulin signaling
via dephosphorylation of the insulin receptor tyrosine residues and downstream substrates to reduce
the role of insulin [62]. It is well accepted that this enzyme is a promising target for hypoglycemic
agent discovery, and a recent review deals with PTP1B inhibitors from natural sources [63]. In the past
decade, several BPs with hypoglycemic activity targeting PTB1B have been discovered. For example,
BP 2.1 (also 6.1 and 7.1.1), BP 2.2 (also 6.2), and BP 2.3 (also 6.3, 7.1.2, 7.3.5, and Scheme 2), isolated from
the marine alga Symphyocladia latiuscula, showed antidiabetic potential by inhibiting PTP1B, and these
compounds also exhibited inhibitory effects on α-glucosidase enzymes, enhancing insulin sensitivity
and glucose uptake [64]. In silico molecular docking simulations also revealed the importance of the
7–OH group for H-bond formation and bromine/phenyl ring number for halogen bond interactions with
the enzymes [64] (see Section 3). Compound 2.4 (Scheme 2), from the red alga Rhodomela confervoides,
represents a potential candidate for further development as an antidiabetic agent. Mechanistically, 2.4
competitively inhibited PTP1B via binding to the catalytic site through hydrogen bonds, activated insulin
signaling in an insulin-independent manner, and ameliorated insulin resistance through enhancing
insulin sensitivity [65,66]. Compound 2.4 also increased glucose uptake in normal and insulin-resistant
C2C12 myotubes and HepG2 cells [65,66]. In vivo, long-term oral administration of BP 2.4 could
significantly reduce the blood glucose level of streptozotocin-induced diabetic mice without obvious
toxic effects [66]. Compound 2.5 (Scheme 2), a synthetic derivative of 2.4 [67], showed significantly
enhanced inhibition of PTP1B, and BP 2.5 directly interacted with PTP1B by binding to the enzyme
catalytic domain through hydrogen bonds in a competitive mode [68]. BP 2.5 ameliorated the
impaired insulin signaling in palmitate-treated C2C12 myocytes. In a db/db mouse diabetic model,
BP 2.5 showed hypoglycemic activity and decreased the serum triglycerides and total cholesterol [68].
Further in vivo study confirmed that oral administration of BP 2.5 exhibited a hypoglycemic effect
significantly, protecting mice from hyperlipidemia, dyslipidemia, and hyperinsulinemia. In addition,
BP 2.5 also enhanced the content of glycogen in the liver and muscles and obviously improved
the number of beta cells in the pancreatic islets [68]. BP 2.6 (Scheme 2) with highly chemical
structural similarity to compound 2.4 was synthesized. Compared with compound 2.7 (also 1.2 and
Scheme 2; IC50 = 2.42 µM), compound 2.6 had a relatively higher inhibitory activity on PTP1B (Table 2;
IC50 = 1.50 µM). Moreover, BP 2.6 could effectively reduce the blood glucose level, total cholesterol, and
HbA1c in the C57BL/KSJ-db/db diabetic mouse model [69]. BP 2.8 (also 1.1, 4.7, 7.3.3, and Scheme 2) is
a marine natural product isolated from the red alga Odonthalia corymbifera, and this compound could
inhibit in vitro the activity of both the PTP1B [70] and α-glucosidase (IC50 = 0.098 µM) [71]. In vivo,
BP 2.8 could efficiently decrease blood glucose, HbA1c, and triglyceride levels, and downregulate
the body weight without influencing food and water intake [70]. BP 2.9 (Scheme 2), which was
isolated from the red alga Rhodomela confervoides, displayed PTP1B inhibition activity with an IC50
value of 1.7 µM. Cellularly, BP 2.9 could increase the activity of insulin and could ameliorate palmitic
acid-induced insulin resistance in C2C12 myotubes [72]. Moreover, BP 2.9 significantly increased
the mRNA expression of carnitine palmitoyl transferase 1B (CPT-1B) and fatty acid binding protein
3 (FABP3) [72], which are closely related to fatty acid oxidation. This suggested that BP 2.9 could
improve fatty acid oxidation by inhibiting PTP1B [72].
BP 2.10 (Scheme 2) was a synthetic derivative of the natural BP 2.9. BP 2.10 also had the function
of inhibiting PTP1B (Table 2; IC50 = 0.89 µM), and its activity was about twofold higher compared
with the lead compound 2.9 (Table 2; IC50 = 1.7 µM) [73]. A preliminary SAR study revealed that the
tricyclic scaffold and multi-bromine atoms (four to five) attached to the aryl rings were critical for
PTP1B inhibition [73]. It has been established that RNA splicing-associated RNA-binding proteins
(RBPs) are able to sensitize the insulin signaling pathway, and therefore significantly decrease the
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blood glucose levels of diabetic BKS db mice [74]. RNA splicing-associated RBPs play a critical role
in the posttranscriptional regulation of, e.g., insulin-like growth factor, and their dysregulation usually
results in diabetes. BP-mediated modulation of RBPs is a promising therapeutic approach to diabetes.
In addition to inhibiting PTP1B, BP 2.10 could also modulate RBPs [75], and the compound was
a promising compound to be developed as a novel hypoglycemic agent. When BP 2.9 was hybridized
with ribose, a new BP derivative 2.11 (Scheme 2) was synthesized. This compound displayed a very
potent and selective inhibitory effect on PTP1B with an IC50 value of 199 nM (Table 2) [76].
To find the specific PTP1B inhibitors, a series of BP derivatives were synthesized and evaluated
in vitro as PTP1B inhibitors, and 2.12 (also 7.2.2 and Scheme 2) was the strongest one (Table 2;
IC50 = 0.68 µM), about fourfold more potent than the lead compound BP 2.7. Further in vivo
experiments also revealed that BP 2.12 possessed promising antidiabetic activities [77]. In addition,
BP 2.12 displayed high selectivity on PTP1B without any effect on other PTPs, such as TCPTP, LAR,
SHP-1, and SHP-2 [77].In order to improve the bioavailability and PTPs selectivity of BPs, a series of
new uncharged BP derivatives was synthesized and BP 2.13 (Scheme 2) could effectively bind to PTP1B
and inhibit PTP1B with an IC50 value of 0.19 ± 0.05 µM (Table 2), and had significant selectivity over
other PTPs [78]. BP 2.13 enhanced both the insulin and leptin signaling pathways while it reduced
the blood glucose level in diabetic BKS db mice in vivo. Pharmacokinetics study revealed that the
compound was absorbed rapidly from the gastrointestinal tract (Tmax = 0.5 h), and widely distributed
in tissues with Vss of 4.25 ± 0.47 L/kg, and t1/2 is 0.40 ± 0.03 h. The bioavailability of this compound
was 8.31 ± 2.96%. Thus, BP 2.13 could serve as a qualified agent to treat diabetes [78].
Aldose reductase (AR) converts glucose to sorbitol in the polyol pathway and it is an important
enzyme to prevent diabetic complications. Some BPs and brominated diarylmethanone derivatives
were synthesized and their activity was evaluated against AR [79,80]. Among these derivatives,
BP 2.14 (Scheme 2) had the greatest inhibitory effects on AR, with an IC50 value of 0.09 µM. Moreover,
these derivatives had strong inhibitory effects on α-glucosidase and α-amylase with IC50 values of
94.27 nM and 38.11 nM, respectively, stronger than the positive control acarbose [79]. Diarylmetane BP
derivatives also possessed excellent inhibitory effect on these metabolic enzymes [80]. Specifically,
the synthesized BPs 2.15–2.22 (Scheme 2) could simultaneously inhibit the activity of AR, α-glucosidase,
and α-amylase enzymes [80]. The inhibitory potency of BPs 2.15–2.22 against AR varied from 0.129 to
1.30 µM. Among BPs having the same number of hydroxyl groups, BP 2.19 (also 3.37) displayed the
greatest inhibitory effect on AR with an IC50 value of 0.129 µM. BPs 2.15–2.22 also exhibited strong
inhibitory effect on α-glucosidase, with IC50 values from 11.72 to 20.05 nM. Among them, BP 2.18 (also
6.16 and 7.2.18) possessed the strongest α-glucosidase inhibition ability, while BP 2.17 (also 3.34, 6.17,
and 7.2.19) was the lowest. BPs 2.15–2.22 also had strong inhibitory effect on α-amylase, with IC50
values from 3.84 to 10.37 nM. Although there was the same number of hydroxyl groups between BP
2.19 and BP 2.21, their α-amylase inhibition activity was totally different, suggesting that the position
of the hydroxyl group plays an important role for their activity [80]. Some newly synthesized BP
derivatives 2.23–2.29 (Scheme 2) also inhibited α-glycosidase activity; among them, BP 2.25 (also 3.27
and 6.9) exhibited the strongest inhibitory effect on α-glycosidase, with an IC50 value of 8.73 nM [81],
indicating its possibly use for the further development of hypoglycemic agents.
Besides the hypoglycemic activity, some marine BPs have the potential to treat obesity. BP 2.30
(also 3.8, 4.9, 5.1, and Scheme 2), isolated from the red alga Polysiphonia morrowii, could inhibit
adipogenesis by regulating expression of adipogenic transcription factors and AMP-activated protein
kinase activation in 3T3-L1 adipocytes and subsequently inhibited intracellular lipid accumulation and
triglyceride level, suggesting the potential to treat obesity [82].
From the recent research progress in the antidiabetic activity of BPs, especially their different
synthetic derivatives, we can see that more in vivo data has been provided. The major mechanisms for
the BPs’ antidiabetic activity have been illustrated systemically and are mainly related to the inhibition
of metabolic enzymes. These preclinical in vivo and in vitro trials suggest that BPs may be promising
candidates for development of antidiabetic agents. Specifically, it is interesting to investigate whether
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the inhibition of α-glucosidase and PTP1B by BPs and their derivatives is not only an important role
for their anticancer activity but also for their antidiabetic activity.Mar. Drugs 2020, 18, x FOR PEER REVIEW 8 of 38 
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Table 2. Antidiabetic activity and names of compounds in Scheme 2.
No. IC50 Names
2.1 7.74 ± 0.14 (a), 2.63 ± 0.11 (b) 2,3,6-tribromo-4,5-dihydroxybenzyl alcohol [64]
2.2 8.50 ± 0.45 (a), 7.24 ± 0.02 (b) 2,3,6-tribromo-4,5-dihydroxybenzyl methyl ether [64]
2.3 5.29 ± 0.08 (a), 1.92 ± 0.02 (b) Bis-(2,3,6-tribromo-4,5-dihydroxybenzyl methyl ether) [64]
2.4 0.84 (a) 3,4-dibromo-5-(2-bromo-3,4-dihydroxy-6-(ethoxymethyl)benzyl) benzene-1,2-diol [65]
2.5 0.63 (a) 3,4-dibromo-5-(2-bromo-3,4-dihydroxy-6-(isopropoxymethyl)benzyl)benzene-1,2-diol [67]
2.6 1.50 (a) 3,4-dibromo-5-(2-bromo-3,4-dihydroxy-6-(isobutoxymethyl)benzyl)benzene-1,2-diol [69]
2.7 2.42 (a) 2,2′,3,3′-tetrabromo-4,4′,5,5′-tetra-hydroxydiphenyl methane [69]
2.8 0.098 (b) Bis(2, 3-dibromo-4, 5-dihydroxybenzyl)ether [71]
2.9 1.7 (a) 3-bromo-4,5-bis(2,3-dibromo-4,5-dihydroxybenzyl)-1,2-benzenediol [72]
2.10 0.89 (a) 1-(2-(2,3-dibromo-4,5-dimethoxybenzyl)-4,5-dimethoxybenzyl)-2,3-dibromo-4,5-dimethoxybenzene [73]
2.11 0.199 (a) (2S,3R,4R,5R)-5-(((3-bromo-4,5-dihydroxybenzoyl)oxy)methyl)tetrahydrofuran-2,3,4-triyl tris(3-bromo-4,5-dihydroxybenzoate) [76]
2.12 0.68 (a) 5,5’-methylenebis(3,4,6-tribromobenzene-1,2-diol) [77]
2.13 0.19 ± 0.05 (a) 3,4-dibromo-5-(5-(4-(4-ethoxyphenoxy)phenyl)oxazol-2-yl)benzene-1,2-diol [78]
2.14 94.27 (b), nM 0.09 (c), 38.11 (d), nM (4-bromo-2,5-dimethoxyphenyl) (phenyl)methanone [79]
2.15 15.23 (b), nM, 0.773 (c), nM, 8.03 (d) (4-bromo-2,5 dihydroxyphenyl) (3,4-dihydroxyphenyl)methanone [80]
2.16 19.64 (b), nM, 0.627 (c), nM, 9.12 (d) 4-bromo-2,5 dihydroxyphenyl) (3,4,5-trihydroxyphenyl)methanone [80]
2.17 20.05 (b), nM, 0.184 (c), nM, 5.83 (d) (2-bromo-4-hydroxyphenyl) (4-hydroxyphenyl)methanone [80]
2.18 11.72 (b), nM, 0.138 (c), nM, 8.56 (d) (2-bromo-4-hydroxyphenyl) (phenyl)methanone [80]
2.19 12.74 (b), nM, 0.129 (c), nM, 3.84 (d) 4-(2-bromo-4-hydroxybenzyl)benzene-1,2 diol [80]
2.20 15.73 (b), nM, 1.30 (c), nM, 6.14 (d) (2-bromo-4-hydroxyphenyl) (phenyl)methanone [80]
2.21 17.52 (b), nM, 0.688 (c), nM, 10.37 (d) 2-bromo-5-(4-hydroxybenzyl)benzene-1,4-diol [80]
2.22 17.11 (b), nM, 0.701 (c), nM, 5.16 (d) 2-benzyl-5-bromobenzene-1,4-diol [80]
2.23 11.55 (b), nM (3-bromo-4-methoxyphenyl) (3,4-dimethoxyphenyl)methanone [81]
2.24 17.77 (b), nM (3-bromo-4-methoxyphenyl) (2,3-dibromo-4-hydroxy-5-methoxyphenyl)methanone [81]
2.25 8.73 (b), nM (2,3-dibromo-4-hydroxy-5-methoxyphenyl) (2,5-dibromo-4-methoxyphenyl)methanone [81]
2.26 12.62 (b), nM (3-bromo-4-methoxyphenyl) (2,5-dibromo-4-methoxyphenyl)methanone [81]
2.27 26.15 (b), nM (2,5-dibromo-4-methoxyphenyl) (phenyl)methanone [81]
2.28 19.52 (b), nM (3-bromo-4-hydroxyphenyl) (3,4-dihydroxyphenyl)methanone [81]
2.29 24.93 (b), nM (2,5-dibromo-4-hydroxyphenyl) (phenyl)methanone [81]
Notes: a, PTP1B; b, α-glucosidase; c, aldose reductase; d, α-amylase; unit for IC50 is µM, unless labeled as nM.
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2.3. Antiradical Activity
Free radicals attack macromolecules (e.g., membrane lipids, proteins, enzymes, DNA, and RNA)
and play a pivotal role in several health disorders such as cancer, diabetes, neurodegenerative
diseases, and inflammatory diseases. Many reports demonstrate that a lot of BPs have potential for
antiradical activity, mainly determined by the 1,1-diphenyl-2-picryl hydrazyl (DPPH) and 2,2′-azinobis
(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) radical scavenging methods.
BPs 3.1–3.6 (Scheme 3), isolated from the marine red alga Rhodomela confervoides, had the ability
to scavenge DPPH and ABTS free radicals, and the IC50 values were shown in Table 3 [83]. Recently,
a novel BP 3.7 (also 7.2.6 and Scheme 3) was isolated from the red alga Symphyocladia latiuscula, and
this compound could effectively scavenge DPPH free radicals, with an IC50 value of 8.5 µM [84]. BP 3.8
(also 2.30, 4.9, 5.1, and Scheme 3) was found in the marine red algal species Rhodomela confervoides,
Polysiphonia morrowii, and Polysiphonia urceolata. Compound 3.8 could scavenge DPPH free radicals,
with an IC50 value of 20.3 µM [85–87]. Further studies showed that BP 3.8 activated ERK- and
Akt-mediated Nrf2 signaling cascades and upregulated HO-1 pathway in keratinocytes, and thus
induced cytoprotective effects against oxidative stress [88]. Moreover, in addition to scavenge DPPH
radicals, BP 3.8 was also reported to scavenge hydroxyl and alkyl radicals. In Vero cells, BP 3.8 could
inhibit H2O2-induced lipid peroxidation, cell death, and apoptosis by inhibiting the production of ROS.
Furthermore, compound 3.8 has been shown to significantly inhibit ROS production, lipid peroxidation,
and cell death in H2O2-stimulated oxidative stress in zebrafish embryos [89]. Compound 3.8 also
protected human keratinocytes from UVB-induced oxidative stress through removing ROS [90] and
inducing the reduced glutathione (GSH) level via the Nrf2-mediated pathway [91]. All these studies
confirmed that 3.8 exerted excellent antioxidant activity both in vitro and in vivo.
Some new nitrogen-containing BPs were isolated from the marine red alga Rhodomela confervoides,
such as BPs 3.9–3.13 (Scheme 3). These BPs showed strong scavenging activity against DPPH free
radicals, with IC50 values from 5.22 to 23.60 µM, while exhibiting moderate activity against ABTS
free radicals, with trolox equivalent antioxidant capacity (TEAC) values from 3.11 to 3.58 mM [92].
Another nitrogen-containing BP 3.14 (Scheme 3) along with 3.15 (Scheme 3), isolated from the marine
red alga Symphyocladia latiuscula, effectively scavenged DPPH free radicals, with IC50 values of
14.5 and 20.5 µg/mL (Table 3) [93]. In one of the few studies using cellular models to evaluate
BPs’ antiradical activity, BPs 3.16–3.19 (Scheme 3) were isolated from the red alga Vertebrata lanosa
and their antiradical activity were investigated, using an oxygen radical absorbance capacity assay,
cellular antioxidant activity assay, and cellular lipid peroxidation assay in normal human lung
fibroblasts [94]. The results showed that BP 3.17 had stronger antiradical activity when compared with
the other three compounds [94].
(R)-rhodomelin A (3.20, Scheme 3) isolated from the red alga Rhodomela confervoides had potential
antiradical activity mainly evaluated by DPPH (IC50 = 3.82 µM) and TEAC assays (IC50 = 4.37 mM).
Similarly, the synthetic (S)-rhodomelin A (3.21, Scheme 3) showed powerful inhibition of DPPH radicals
with an IC50 value of 8.9 µM. Although (S)-rhodomelin A was not so strong as (R)-rhodomelin A (3.20),
it was more potent than the positive control BHT (IC50 = 82.13 µM) [44].
In addition to the natural BPs, many kinds of synthetic BP derivatives have been reported to
have good antiradical activities. For instance, 5,2′-dibromo-2,4′,5′-trihydroxydiphenylmethanone
(3.22, 5.4, and Scheme 3) and 2,3-dibromo-4,5-dihydroxydiphenylmethanone (3.23 and Scheme 3),
were able to protect human umbilical vein endothelial cells (EC50 = 0.4 and 0.8 µM) from H2O2-induced
oxidative stress injury [95]. When a series of nitrogen-containing heterocycles such as piperidine,
piperazine, and imidazole replaced the OH group at the 2-position of 3.22, the products also showed
moderate to potent cytoprotective activity against H2O2-induced injury in EAhy926 cells with 3.24
(Scheme 3; EC50 = 0.9 µM) being the most potent compound. A SAR study revealed that the antiradical
ability of these analogues strengthened with an increasing number of heterocycles and hydroxyl
groups [42]. Furthermore, a molecular docking study demonstrated that compound 3.24 could
interact with Keap1, and thus in turn modulate Keap1-Nrf2 protein–protein interaction in order to
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activate Nrf2-induced downstream protective genes from oxidative stress damage [42] (see Section 3).
Some novel synthetic diarylmethanone BPs 3.25–3.31 (Scheme 3) also showed antiradical abilities.
These compound could effectively clear DPPH free radicals, with IC50 values from 23.10 to 34.65 µg/mL,
but they demonstrated a relatively weaker ability to scavenge ABTS radicals, with IC50 values from
69.3 to 231 µg/mL [81]. In a recent study, some new BPs 3.32–3.37 (Scheme 3), which had antiradical
activities, were synthesized [96]. BPs 3.32–3.37 could effectively scavenge DPPH free radicals with IC50
values from 13.32 to 16.44 µg/mL, and ABTS free radicals with IC50 values from 5.08 to 7.35 µg/mL.
Based on these IC50 values, it is concluded that the antiradical capacity of BPs 3.32–3.37 does not vary
a lot, indicating that the number of hydroxyl groups and the position of the bromine atom in these
compounds have little effect on the antiradical capacity [96].
In the past several decades, the antioxidant activities of BPs are still of interest. The above
reported studies further confirm BPs to be one of the potential candidates for the prevention of chronic
diseases related to oxidative stress, such as cancer, diabetes, neurodegeneration, and inflammation.
Compared with ten years ago, in addition to the natural BPs, more derivatives of BPs have been
synthesized and evaluated for their antiradical activity. Moreover, both cellular and animal models
have been tested to assess the antiradical capacity of marine BPs, providing more conceivable
experimental data.Mar. Drugs 2020, 18, x FOR PEER REVIEW 12 of 38 
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Table 3. Antiradical activity and names of compounds in Scheme 3.
No. IC50/EC50 Names
3.1 9.52 ± 0.04 (a), 2.06 ± 0.08 (b) 3,4-dibromo-5-((methylsulfonyl)methyl)benzene-1,2-diol [83]
3.2 7.43 ± 0.1 (a), 2.11 ± 0.04 (b) 3,4-dibromo-5-((2,3-dihydroxypropoxy)methyl)benzene-1,2-dio [83]
3.3 20.47 ± 0.07 (a), 1.87 ± 0.02 (b) 5-(aminomethyl)-3,4-dibromobenzene-1,2-dio [83]
3.4 19.84 ± 0.06 (a), 2.87 ± 0.11 (b) 2-(2,3-dibromo-4,5-dihydroxyphenyl)acetic acid [83]
3.5 50.58 ± 0.23 (a), 1.60 ± 0.04 (b) 3-bromo-5-(hydroxymethyl)-2-methoxyphenol [83]
3.6 8.72 ± 0.05 (a), 3.68 ± 0.12 (b) (E)-4-(2-bromo-4,5-dihydroxyphenyl)but-3-en-2-one [83]
3.7 8.5 (a) (2R)-2-(2,3,6-tribromo-4,5-dihydroxybenzyl)-cyclohexanone [84]
3.8 20.3 (a) 3-bromo-4,5-dihydroxybenzaldehyde [85]
3.9 5.22 ± 0.04 (a), 2.87 ± 0.1 (b) 3-(2,3-dibromo-4,5-dihydroxybenzyl)pyrrolidine-2,5-dione [92]
3.10 5.70 ± 0.03 (a), 2.14 ± 0.08 (b) Methyl 4-(2,3-dibromo-4,5-dihydroxybenzylamino)-4-oxobutanoate [92]
3.11 5.43 ± 0.02 (a), 2.31 ± 0.11 (b) 4-(2,3-dibromo-4,5-dihydroxybenzylamino)-4-oxobutanoic acid [92]
3.12 23.60 ± 0.1 (a), 2.11 ± 0.04 (b) 3-bbromo-5-hydroxy-4-methoxy-benzamide [92]
3.13 20.81 ± 0.08 (a), 2.36 ± 0.08 (b) 2-(3-bromo-5-hydroxy-4-methoxyphenyl)acetamide [92]
3.14 14.5 (a), µg/mL Methyl 4-(3-(2,3,6-tribromo-4,5-dihydroxybenzyl)ureido)butanoate [93]
3.15 20.5 (a), µg/mL 2-(3-(2,5-dibromo-3,4-dihydroxyphenyl)-1-methoxy-1-oxopropan-2-yl)maleic acid [93]
3.20 3.82 ± 0.01 (a), 4.37 ± 0.24 (b) (R)-Rhodomelin A [44]
3.21 8.90 (a) (S)-Rhodomelin A [44]
3.22 0.4 (c) 5,2′-dibromo-2,4′,5′-trihydroxydiphenylmethanone [97]
3.23 0.8 (c) 2,3-dibromo-4,5-dihydroxydiphenylmethanone [97]
3.24 0.9 (c) 1-(4-(4-bromo-2-(2-bromo-4,5-dihydroxybenzoyl)benzyl)piperazin-1-yl)ethan-1-one [42]
3.25 31.50 (a), 198.00 (b), µg/mL (4-bromo-2,5-dimethoxyphenyl) (phenyl)methanone [81]
3.26 28.87 (a), 231.00 (b), µg/mL (3-bromo-4-methoxyphenyl) (3,4-dimethoxyphenyl)methanone [81]
3.27 34.65 (a), 173.25 (b), µg/mL (3-bromo-4-methoxyphenyl) (2,3-dibromo-4-hydroxy-5-methoxyphenyl)methanone [81]
3.28 28.88 (a), 138.6 (b), µg/mL (2,3-dibromo-4-hydroxy-5-methoxyphenyl) (2,5-dibromo-4-methoxyphenyl)methanone [81]
3.29 26.65 (a), 231.00 (b), µg/mL (3-bromo-4-methoxyphenyl) (2,5-dibromo-4-methoxyphenyl)methanone [81]
3.30 23.10 (a), 69.3 (b), µg/mL (2,5-dibromo-4-methoxyphenyl) (phenyl)methanone [81]
3.31 33.00 (a), 115.50 (b), µg/mL (3-bromo-4-hydroxyphenyl) (3,4-dihydroxyphenyl)methanone [81]
3.32 16.44 (a), 6.55 (b), µg/mL (4-bromo-2,5-dihydroxyphenyl) (3, 4-dihydroxyphenyl)methanone [96]
3.33 14.43 (a), 6.86 (b), µg/mL (4-bromo-2,5-dihydroxyphenyl) (3,4,5-trihydroxyphenyl)methanone [96]
3.34 19.24 (a), 7.35 (b), µg/mL (2-bromo-4-hydroxyphenyl) (4-hydroxyphenyl)methanone [96]
3.35 13.32 (a), 6.86 (b), µg/mL 2-benzyl-5-bromobenzene-1,4-diol [96]
3.36 13.86 (a), 5.08 (b), µg/mL 2-bromo-5-(4-hydroxybenzyl)benzene-1,4-diol [96]
3.37 15.75 (a), 7.71 (b), µg/mL 4-(2-bromo-4-hydroxybenzyl)benzene-1,2-diol [96]
Notes: a, IC50 for DPPH inhibition, and unit for IC50 is µM, unless labeled as µg/mL; b, IC50 for TEAC inhibition and unit for IC50 is mM, unless labeled as µg/mL; c, EC50 (µM) for
H2O2 inhibition.
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2.4. Antimicrobial Activity
Microbial infection is still a big challenge worldwide due to drug resistance. One of the major
challenges is the limitation of screening libraries [98,99]. Different marine natural products may
contribute to improve these chemical libraries, and it has been reported that a lot of BPs possess potent
antimicrobial activities.
Obtained from the marine red alga Symphyocladia latiuscula, compounds 4.1–4.4 (Scheme 4) revealed
antimicrobial activities against Candida albicans with the minimum inhibitory concentration (MIC)
values in the range of 10 to 37.5 µg/mL (Table 4) [5,6]. Porphyromonas gingivalis is an important causative
pathogen in human periodontitis, and gingipain R (Rgp) as well as ashemagglutinin A (HgA) proteins
play significant roles in the infectious pathway of the pathogen [4]. A methanol extract of the red
alga Kappaphycus, rich in BPs, showed in vitro antibacterial activities against P. gingivalis via inhibiting
the gingipain and hemagglutination [4]. BPs were shown to inhibit and control the virulent proteins
produced by P. gingivalis, thus suggesting their possible applicability in commercial dental products.
From the marine red alga Kappaphycus sp, the aldehyde 4.5 was isolated (Scheme 4). It exhibited
inhibitory activity against both Gram-positive and Gram-negative bacteria [100]. An antimicrobial
test by the disc diffusion method showed that BP 4.5 had an obvious inhibitory effect on Pseudomonas
fluorescence and Staphylococcus aureus [100]. Aside from the compounds mentioned above, synthetic BP
4.6 (Scheme 4) showed a favorable antibacterial effect against Staphylococcus epidermidis (MIC = 0.556µM),
stronger than the positive control ciprofloxacin [97].
In addition to the human infectious microorganism, some BPs also showed significant effects against
phytopathogenic fungi. For example, compound 4.7 (also 1.1, 2.8, 7.3.3, and Scheme 3), isolated from
algae Leathesia nana, possessed significant antifungal activity against various phytopathogenic fungi,
such as Botrytis cinereal, Valsa mali, and Fusarium graminearum [51]. Among these pathogens,
Botrytis cinereal was the most sensitive to 4.7 (Table 4; IC50 = 31 µg/mL). Moreover, 4.7 inhibited
the spore germination and the mycelial growth, disrupted the cell membrane, and targeted DNA of
Botrytis cinereal. This work provided evidence that BPs could be further developed as antifungal agents
and applied in the control of phytopathogenic fungi [51].
Moreover, BPs were also reported to have a certain effect against fish virus. From the red alga
Polysiphonia morrowii, two BPs 4.8–4.9 (Scheme 4) were isolated and characterized [86]. BP 4.8 inhibited
fish pathogenic infectious hematopoietic necrosis virus (IHNV) and infectious pancreatic necrosis virus
(IPNV) with values of effective concentration for 50% of maximal effect (EC50) of 19.04 and 26 µM,
respectively, while BP 4.9 (also 2.30, 3.8, and 5.1) only exhibited antiviral activity against IHNV with
an EC50 of 75 µM (Table 4) [86]. These findings indicated that BPs had potential to be developed as
therapeutic agents against fish viral diseases.
A series of meta-amido BPs have been designed and synthesized in recent years, which had
good inhibitory effects on mycobacterium tuberculosis bacteria and multidrug resistant strains [101].
Compounds 4.10–4.13 (Scheme 4) all showed powerful inhibition against the growth of mycobacterium
tuberculosis bacteria H37Ra strain (Table 4; MIC = 0.25–12.5µg/mL), while they could not inhibit normal
Gram-positive and Gram-negative bacteria, indicating their high specificity in the inhibition of tubercle
bacillus. Compounds 4.12 and 4.13 also exhibited moderate inhibitory activity against MDR-TB strains
of Mycobacterium tuberculosis. Furthermore, these BPs showed good metabolic stability in rat livers [101].
Considering the above results, meta-amido BPs can become a novel type of anti-tubercular agents.
BPs from marine algae have potential antimicrobial activity that may contribute to the development
of antimicrobial dugs against human pathogens, phytopathogenic fungi, and fish virus. More studies
are needed to address the toxicity in vivo, the mechanism of the antimicrobial action, and the metabolic
stability of marine BPs as antimicrobial agents.
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Table 4. Antimicrobial activity and names of compounds in Scheme 4.
No. MIC/IC50/EC50 and Microbe Names
4.1 MIC 25 µg/mL (a) Methyl 4-{(2,5-dibromo-3,4-dihydroxybenzyl)[(2,3,6-tribromo-4,5-dihydroxybenzyl)carbamoyl]amino}butanoate [5]
4.2 MIC 12.5 µg/mL (a) 2,5-dibromo-3,4-dihydroxy-6-(2,3,6-tribromo-4,5-dihydroxybenzyl)benzyl methyl ether [5]
4.3 MIC 10 µg/mL (a) symphyocladin G [6]
4.4 MIC 37.5 µg/mL (a) 2,3,6-tribromo-4,5-dihydroxybenzyl methyl sulphoxide [6]
4.6 MIC 0.556 µg/mL (b) 2,4,6,2′,4′,6′-Hexabromodiorcinol [97]
4.7 IC50 31 µg/mL (c) Bis-(2,3-dibromo-4,5-dihydroxybenzyl)-ether [51]
4.8 EC50 19.04 µM (IHNV)EC50 26 µM (IPNV)
2, 3-bromo-4,5-dihydroxybenzyl methyl ether [86]
4.9 EC50 75 µM (IHNV)EC50 > 100 µM (IPNV)
3-bromo-4,5-dihydroxybenzaldehyde [86]
4.10 MIC 12.5 µg/mL (d) 4-bromo-3-hydroxy-N-phenylbenzamide [101]
4.11 MIC 12.5 µg/mL (d) 5-(benzylamino)-2-bromophenol [101]
4.12 MIC 0.5 µg/mL (d) N-(4-bromo-3-hydroxyphenyl)-4-(trif luoromethoxy)-benzamide [101]
4.13 MIC 0.25 µg/mL (d) N-(4-bromo-3-hydroxyphenyl)-4-(trif luoromethyl)-benzamide [101]
Notes: a, Candida albicans (ATCC 10231); b, Staphylococcus epidermidis; c, Botrytis cinereal; d, Mycobacterium
tuberculosis H37Ra.
2.5. Anti-Inflammatory Activity
In the past decade, the anti-inflammatory activities of BPs have attracted great attention.
Inflammation is the response triggered by damage to living tissues and has a close relationship
to many diseases. Immunoglobulin E (IgE), an important target for atopic dermatitis, induces mast
cells to produce inflammatory mediators including various cytokines. Isolated from the red alga
Polysiphonia morrowii, 3-bromo-4,5-dihydroxybenzaldehyde 5.1 (also 2.30, 3.8, 4.9, and Scheme 5) was
reported to alleviate IgE-mediated inflammatory responses in an atopic dermatitis mouse model and
RAW 264.7 macrophages, suggesting their therapeutic potential for treating allergic inflammation,
e.g., atopic dermatitis [102]. Further studies showed that BP 5.1 reduced the IgE level and inhibited the
production of interleukin-6 (IL-6) by downregulating the nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) and signal transducer and activator of transcription 1 (STAT1) pathways [102],
two major signaling pathways involved in cellular inflammation.
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Macrophage activation is associated with diverse pathological processes such as inflammatory
disorders, and the activated macrophages yield various inflammatory mediators [7]. Further studies
showed that 5.1 reduced CD68+ macrophages, M1 and M2 macrophages infiltration, inhibited the
phosphorylation of NF-κB, suppressed the secretion of pro-inflammatory cytokines in the injured
hearts, and finally, improved cardiac function recovery [103]. This anti-inflammatory activity of 5.1
suppressed the inflammatory factors in myocardial ischemia and reperfusion, and showed myocardial
protection via the Akt-PGC1a-Sirt3 pathway [104].
Another BP from the red alga Polysiphonia morrowii, bis (3-bromo-4,5-dihydroxybenzyl) ether 5.2
(Scheme 5), significantly decreased lipopolysaccharide (LPS)-induced NO, PGE2, and pro-inflammatory
cytokines release via inhibiting the ROS-mediated ERK signaling pathway in RAW 264.7 macrophage
cells [7], and thus showed potential in the treatment of inflammatory diseases.
5,2′-dibromo-2,4′,5′-trihydroxydiphenylmethanone 5.3 (Scheme 5), a novel synthetic marine BP
derivative, displayed powerful anti-inflammatory effects and could be used in the treatment of acute
pyelonephritis (APN) [105]. BP 5.3 could reduce kidney viscera indices and microbial counts in APN
rats. Moreover, it inhibited the production of inflammatory mediators, including interleukin-1β (IL-1β)
and interleukin-6 (IL-6), and increased the number of CD8+ and CD4+ T cells, which serve as important
inflammatory cytokines and immune cells [105], indicating its further application against renal tissue
injury and APN. Another new BP 5.4 (also 3.22) with anti-inflammatory activity was synthesized.
This compound could reduce the expression of inflammatory cytokines, including IL-6, IL-1β,and
tumor necrosis factor-α (TNF-α), and could increase the level of anti-inflammatory cytokine IL-10 [106].
BP 5.4 could also reduce the production of nitric oxide and ROS to achieve anti-inflammatory effects.
Moreover, BP 5.4 could enhance the phagocytic capacity and reduce LSP-induced inflammation
in RAW264.7 cells by activating the PI3K/AKT signaling pathway [106].
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2.6. Anti-Alzheimer’s Disease (AD) and Parkinson’s isease (PD) Activity
Neurodegenerative diseases such as AD and PD are major causes of death worldwide and
characterized by a progressive loss of specific neuronal cells. Although the discovery of new drugs
for these neurod generative diseases is still challeng ng, in recent years, natural BPs have shown
protective activities from different neurodegenerative diseases, and therefore are good candidates
for the development of new drugs. AD is related to cholinergic deficiency, β-amyloid deposition,
and formation of tau tangles. Thus, cholinesterases (ChEs, e.g., AChE, BChE), β-site amyloid precursor
protein cleaving enzym 1 (BACE1), and glycogen synthase kinase-3β (GSK-3β) are considered as
important targets for anti-AD drugs [9]. PD is another common neurodegenerative disease and ChEs
are the major targets for its treatment [107].
Marine algae have been reported to contain bioactive s bstances for AD treatment, such as the
first marine-derived anti-AD drug sodiu oligoma nate (GV-97 ) [108]. Some marine BPs have also
shown potential anti-AD activities. BP 6.1 (also 2.1 and 7.1.1), BP 6.2 (also 2.2) and BP 6.3 (also 2.3,
7.1.2, and 7.3.5) (Scheme 6), isolated from Symphyocladia latiuscula (Harvey) Yamada, had significant
effects as potent inhibitors of enzymes, including ChEs, BACE1, and GSK-3β. Among them, compound
6.3 exhibite the most pot n i hibitory activity against AChE, BChE, a d BACE1 (Table 5; IC50
values of 2.66, 4.03, and 2.32 µM, respectively). Studies showed that the 7−OH group and bromine
number for hydrogen bond and halogen bond interactions seemed important for inhibition of these
enzymes [9] (see Section 3). More ver, B s 6.1–6.3 exhibited ore than 50% inhibiti n of self-induced
Aβ25–35 aggregation [9], which may be another m chanism for their anti-AD activity. In addition to
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anti-AD activity, BPs 6.1–6.3 have also been reported as inhibitors of human monoamine oxidase-A
(hMAO-A) [109], which catalyzes the inactivation of multiple neurotransmitters in the treatment
of PD. Furthermore, the same research group found that BPs 6.1–6.3 were also good dopamine
D3/D4 receptor agonists. BP 6.3 was the most promising dopamine D4 receptor agonist exhibiting
EC50 value at very low micromolar levels (Table 5) [109]. Since AChE, BChE, BACE1, hMAO-A,
and dopaminergic receptors are closely related to the neurodegenerative diseases such as AD and PD,
these BPs compounds can possibly be developed as new drugs for the treatment of neurodegenerative
disorders. Using PreADMET (v2.0, YONSEI University, Seoul, Korea), ADME predictions of BPs
6.1–6.3 revealed an excellent percentage of plasma protein binding, good intestinal absorption, and high
blood−brain barrier penetration [9]. In addition to the BPs mentioned above, BPs 6.4–6.6 (Scheme 6)
containing a 4-phenylbutenone moiety, which were isolated from the red alga Rhodomela confervoides,
also showed ChEs inhibition. BPs 6.4–6.6 inhibited AChE, with Ki values from 19.02 ± 6.15 to
32.38 ± 8.01 pM. BPs 6.4–6.6 also had the ability to inhibit BChE, with Ki values from 8.013 ± 3.06 to
13.28 ± 0.07 pM [110].
Some synthetic derivatives of the BPs also showed AChE inhibitory activity. For example, BPs
6.7–6.13 (Scheme 6) showed good inhibition of AChE, with Ki values from 8.94± 0.73 to 59.45± 14.97 nM.
Among them, 6.11 (also 2.27 and 3.29), which have two bromines in para-position and one methoxy,
showed the strongest inhibitory ability of AChE, with a Ki value of 8.94 ± 0.73 nM [81]. In another
research study, a series of BP derivatives with a CH3SO2 group were synthesized, and these compounds
had anticholinergic activities [111]. Among these compounds, 6.14 (Scheme 6) inhibited the activity
of AChE and BChE, with Ki values of 1.53 ± 0.23 and 0.93 ± 0.20 nM, respectively, while 6.15
(Scheme 6) inhibited AChE and BChE, with Ki values of 0.84 ± 0.12 and 3.73 ± 1.03 nM, respectively.
Comparing these two compounds, BP 6.14, with two hydroxyl groups and one bromine group,
had stronger activity toward BChE, whereas BP 6.15, with two hydroxyl groups and three bromine
groups, had stronger activity toward AChE [111]. In addition, another two synthetic BPs 6.16 (also 2.18
and 7.2.18) and 6.17 (also 2.17, 3.34, 7.2.19, and Scheme 6) have shown inhibitory activity against
BChE, with IC50 values of 22.35 and 30.13 nM, respectively. However, these two compounds had even
stronger inhibitory activity against AChE, with IC50 values of 10.82 and 13.07 nM, respectively [96].
In another study, a new type of methylated BP 6.18 (Scheme 6) without phenolic hydroxyl groups was
synthesized, and exerted an inhibitory effect on AChE activity, with a Ki value of 159.6 ± 21.9 nM [46].
All the above-mentioned results indicate that marine BPs and their derivatives are excellent
inhibitors of ChEs; thus, they are candidates for the treatment of neurodegenerative diseases such as
AD and PD.
Table 5. Anti-AD and anti-PD activities and names of compounds in Scheme 6.
No. IC50/Ki/EC50 Names
6.1 7.31 ± 0.25 (a), 8.95 ± 2.18 (b), 5.16 ± 0.60 (c),229.42 ± 12.05 (d), 204.94 ± 4.46 (e) 2,3,6-tribromo-4,5-dihydroxybenzylalcohol [9,109]
6.2 9.61 ± 0.35 (a), 14.41 ± 0.27 (b), 4.79 ± 0.82 (c),140.01 ± 15.08 (d), 63.16 ± 0.4 (e) 2,3,6-tribromo-4,5-dihydroxybenzyl methyl ether [9,109]
6.3 2.66 ± 0.24 (a), 4.03 ± 0.15 (b), 2.32 ± 0.10 (c),56.46 ± 2.48 (d), 89.31 ± 2.45 (e), 18.72 ± 2.80 (f) Bis(2,3,6-tribromo-4,5-dihydroxybenzyl)ether [9,109]
6.4 32.38 ± 8.01 (a), 8.013 ± 3.06 (b), pM, Ki (E)-4-(3-bromo-4,5-dihydroxyphenyl)but-3-en-2-one [110]
6.5 24.38 ± 2.73 (a), 13.28 ± 0.07 (b), pM, Ki (E)-4-(2-bromo-4,5-dihydroxyphenyl)but-3-en-2-one [110]
6.6 19.02 ± 6.15 (a), 11.84 ± 3.47 (b), pM, Ki (E)-4-(2,3-dibromo-4,5-dihydroxyphenyl)but-3-en-2-one [110]
6.7 45.72 ± 3.30 (a), nM, Ki (4-bromo-2,5-dimethoxyphenyl) (phenyl)methanone [81]
6.8 37.29 ± 0.25 (a), nM, Ki (3-bromo-4-methoxyphenyl) (3,4-dimethoxyphenyl)methanone [81]
6.9 14.23 ± 1.99 (a), nM, Ki (3-bromo-4-methoxyphenyl) (2,3-dibromo-4-hydroxy-5-methoxyphenyl)methanone [81]
6.10 21.96 ± 7.60 (a), nM, Ki (2,3-dibromo-4-hydroxy-5-methoxyphenyl) (2,5-dibromo-4-methoxyphenyl)methanone [81]
6.11 8.94 ± 0.73 (a), nM, Ki (3-bromo-4-methoxyphenyl) (2,5-dibromo-4-methoxyphenyl)methanone [81]
6.12 59.45 ± 14.97 (a), nM, Ki (2,5-dibromo-4-methoxyphenyl) (phenyl)methanone [81]
6.13 27.55 ± 9.73 (a), nM, Ki (3-bromo-4-hydroxyphenyl) (3,4-dihydroxyphenyl)methanone [81]
6.14 1.53 ± 0.23 (a), 0.93 ± 0.20 (b), nM, Ki 3,4-dibromo-5-((methylsulfonyl)methyl)benzene-1,2-diol [111]
6.15 0.84 ± 0.12 (a), 3.73 ± 1.03 (b), nM, Ki 3,4,6-tribromo-5-((methylsulfonyl)methyl)benzene-1,2-diol [111]
6.16 10.82 (a), 22.35 (b), nM (2-bromo-4-hydroxyphenyl) (phenyl)methanone [96]
6.17 13.07 (a), 30.13 (b), nM (2-bromo-4-hydroxyphenyl)(4-hydroxyphenyl)methanone [96]
6.18 159.6 ± 21.9 (a), nM, Ki 2,4-dibromo-4-(2,3-dibromo-4,5-dimethoxyphenyl)-3-methylbutanoic acid [46]
Notes: a, AChE; b, BChE; c, BACE1; d, GSK-3β; e, hMAO-A; unit for IC50 is µM and nM, unless labeled for Ki is nM
and pM. f, D4R, and unit for EC50 is µM.
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2.7. Other Bioactivity
2.7.1. Tyrosinase Inhibitory Activity
Tyrosinase is a rate-limiting enzyme for human melanin formation. Therefore, targeting tyrosinase
can be used for the development of anti-melanin agents such as depigmenting agents in cosmetology
or for the treatment of skin diseases such as hyperpigmentation [112]. BPs 7.1.1 (also 2.1 and 6.1)
and 7.1.2 (also 2.3, 6.3, 7.3.5, and Scheme 7), isolated from S. latiuscula, have been shown to inhibit
competitively tyrosinase activity, with IC50 values of 10.78 ± 0.19 and 2.92 ± 0.04 µM, respectively.
A molecular docking study found that catalytic hydrogen bond, hydrogen and halogen interactions
contributed to the enzyme inhibition activity (see Section 3). In addition, BPs 7.1.1 and 7.1.2 also
showed dose-dependent inhibition of tyrosinase expression levels, melanin content, and intracellular
tyrosinase activity in B16F10 melanoma cells [113]. Therefore, the strong tyrosinase inhibitory activity
exhibited by these marine BPs isolated from S. latiuscula, suggests these algae as a possible source for
depigmenting agents used in cosmetology.
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2.7.2. Carbonic Anhydrase (CA) Inhibitory Activity
CA catalyzes the reversible hydration of carbon dioxide into bicarbonate and protons, and it
participates in important biological processes in the human body, including acid-base balance,
respiration, carbon dioxide, and ion transport. Therefore, inhibiting or activating CA is beneficial to
diseases such as edema, glaucoma, obesity, cancer, epilepsy, and osteoporosis [114]. CA inhibition
activity is another newly discovered function of marine BPs. For example, BPs 7.2.1 and 7.2.2 (also
2.12 and Scheme 8), obtained from the red alga Symphyocladia latiuscula, had weak inhibitory effects on
human carbonic anhydrase (hCA) II with IC50 values of 86.4 and 38.29 µM, respectively. However,
the derivative 7.2.3 (Scheme 8) had a stronger activity (IC50 = 0.7 µM) [115]. BP 7.2.4 (Scheme 8) was
isolated from the Caribbean red alga Vidalia obtusaloba, and had strong inhibitory effects on hCA I, II,
IV, and VI, with Ki values of 12.24, 1.13, 1.84, and 3.41 µM, respectively, whereas BP 7.2.5 (Scheme 8),
which was the fully methylated derivative of 7.2.4, had weaker inhibition against hCA I, II, IV, and VI,
with Ki values of 93.42, 78.49, 57.61, and 45.36 µM, respectively, indicating the importance of the -OH
groups in the activity against hCA [116]. BP 7.2.6 (also 3.7 and Scheme 8), isolated from the red alga
Symphyocladia latiuscula [84], also exhibited good inhibitory activity on hCA I, II, IV, and VI, with Ki
values of 1.67, 0.56, 1.08, and 0.59 µM, respectively [41]. In addition to the natural BPs mentioned above,
some synthetic BP derivatives also possess good inhibitory activity on CA. For instance, based on
the reduced form of BP 7.2.6, four O-methylated derivatives 7.2.7–10 (Scheme 8) were synthesized
in recent work and showed powerful hCA I, II, IV, and VI inhibitory activity (the Ki values are given
in Table 6). The structures of BPs 7.2.7 and 7.2.9 are cis, whereas those of BPs 7.2.8 and 7.2.10 are trans.
The comparison of these four compounds indicated that the difference in configuration had little effect
on the hCA inhibitory activity [41]. Moreover, the natural BP 7.2.11 (Scheme 8) was synthesized and
also revealed inhibitory activity for hCA I and II, with Ki values of 32.7 and 1.26 µM, respectively [39].
Based on BP 7.2.11, the same research group also synthesized four BPs 7.2.12–15 (Scheme 8) which
exhibited enhanced inhibitory activity for hCA I and II, with Ki values in the range of 13.7–28.5 µM
and 0.65–0.92 µM, respectively [39]. Compared with the BPs 7.2.13–15, 7.2.12 showed better inhibition
activity toward hCA I and II, with Ki values of 13.7 and 0.65 µM, suggesting the attenuation effect of
the bromide moiety [39]. When compared with the natural compound BP 7.2.11 with hydrophobic
groups, BPs 7.2.12–15 containing hydroxyl groups had stronger inhibition against hCA I and II [39].
Some new BPs 7.2.16–21 (Scheme 8) were synthesized and reported to have hCA I and II inhibitory
activity [96]. Among them, BPs 7.2.16–19 inhibited hCA I and II, with IC50 values from 6.79 to 8.45 and
5.97 to 9.24 nM, respectively. However, methylated derivatives 7.2.20 and 7.2.21 had similar inhibitory
activity on hCA I, with IC50 values of 7.61 and 7.51 nM, and on hCA II, with IC50 values of 5.58
and 6.07 nM, respectively. The primary SAR indicated that the hydroxyl and methoxy groups had
little effect on the hCA inhibitory activity of these compounds. Moreover, among BPs 7.2.16–21 there
was no significant difference in hCA I and II inhibition, indicating that they were non-specific hCA
inhibitors [96].
In another study, methylated BPs 7.2.22–24 (Scheme 8) were synthesized and exhibited excellent
hCA I inhibition profile with Ki values of 8.4 ± 2.3, 10.7 ± 2.9, and 7.8 ± 0.9 nM, respectively [46].
In addition to hCA I, BP 7.2.22 together with 7.2.25 (Scheme 8), also had strong inhibition activity on
hCA II, with Ki values of 48.3 ± 1.3 and 43.1 ± 1.7 nM, respectively [46]. In general, both the natural
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BPs and their synthesized derivatives may be candidates as potent CA inhibitors, and thus protect the
body from a series of diseases such as edema, glaucoma, obesity, cancer, epilepsy, and osteoporosis.
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No. Ki/IC50 (µM) Names
7.2.1 86.4 (a), IC50 3,4,6-tribromo-5-(2,5-dibromo-3,4-dihydroxybenzyl)benzene-1,2-diol [115]
7.2.2 38.29 (a), IC50 5,5′-methylene bis(3,4,6-tribromo-benzene-1,2-diol) [115]
7.2.3 0.7 (a), IC50 (2-bromo-3,4-dihydroxyphenyl) (2,3-dibromo-4,5-dihydroxyphenyl)methanone [115]
7.2.4 1.13 (a), 1.84 (b), 12.24 (c), 3.41 (d) 2-bromo-4,6-bis(2,3-dibromo-4,5-dihydroxybenzyl)benzene-1,3,5-triol [116]
7.2.5 78.49 (a), 57.61 (b), 93.42 (c), 45.36 (d) 4-bromo-2,6-bis(2,3-dibromo-4,5-dimethoxybenzyl)-3,5-dimethoxyphenol [116]
7.2.6 0.56 (a), 1.08 (b), 1.67 (c), 0.59 (d) 2(R)-2-(2,3,6-tribromo-4,5-dihydroxybenzyl)cyclohexanone [41]
7.2.7 0.38 (a), 0.85 (b), 1.04 (c), 0.48 (d) 1R(S),2R(S)-2-(3-bromo-4,5 dimethoxybenzyl)cyclohexanol [41]
7.2.8 0.38 (a), 0.87 (b), 1.03 (c), 0.47 (d) 1(R)S,2S(R)-2-(3-bromo-4,5-dimethoxybenzyl)cyclohexanol [41]
7.2.9 0.41 (a), 0.93 (b), 1.12 (c), 0.51 (d) 1R(S),2R(S)-2-(2,3-dibromo-4,5-dimethoxybenzyl)cyclohexanol [41]
7.2.10 0.39 (a), 0.88 (b), 1.10 (c), 0.47 (d) 1(R)S,2S(R)-2-(2,3-dibromo-4,5-dimethoxybenzyl)cyclohexanol [41]
7.2.11 1.26 (a), 32.7 (c) 3,4-dibromo-5-(2,3-dibromo-4,5-dihydroxybenzyl)-6-(ethoxymethyl)benzene-1,2-diol [39]
7.2.12 0.65 (a), 13.7 (c) (4,5-dihydroxy-2-methylphenyl) (3,4-dihydroxyphenyl)methanone [39]
7.2.13 0.74 (a), 18.5 (c) (3-bromo-4,5-dihydroxy-2-methylphenyl) (3,4-dihydroxyphenyl)methanone [39]
7.2.14 0.83 (a), 22.6 (c) (3-bromo-4,5-dihydroxy-2-methylphenyl) (2-bromo-4,5-dihydroxyphenyl)methanone [39]
7.2.15 0.92 (a), 28.5 (c) (2-bromo-4,5-dihydroxyphenyl) (4,5-dihydroxy-2- methylphenyl)methanone [39]
7.2.16 9.24 (a), 7.87 (c), (4-bromo-2, 5-dihydroxyphenyl) (3, 4-dihydroxyphenyl)methanone [96]
7.2.17 5.97 (a), 8.15 (c), (4-bromo-2, 5-dihydroxyphenyl) (3, 4, 5-trihydroxyphenyl)methanone [96]
7.2.18 6.93 (a), 8.45 (c), (2-bromo-4-hydroxyphenyl) (phenyl)methanone [96]
7.2.19 6.18 (a), 6.79 (c), (2-bromo-4-hydroxyphenyl) (4-hydroxyphenyl)methanone [96]
7.2.20 5.58 (a), 7.61 (c), (2-bromo-4-methoxyphenyl) (phenyl)methanone [96]
7.2.21 6.07 (a), 7.51 (c), (2-bromo-4-methoxyphenyl) (4-methoxyphenyl)methanone [96]
7.2.22 8.4 ± 2.3 (c), 48.3 ± 1.3 (a), nM (1R*,2R*,3R*)-ethyl 2-(2-bromo-4,5-dimethoxyphenyl)-3-methylcyclopropane-1-carboxylate [46]
7.2.23 10.7 ± 2.9 (c), nM (1S*,2R*,3R*)-ethyl 2-(2,6-dibromo-3,4-dimethoxyphenyl)-3-methylcyclopropanecarboxylate [46]
7.2.24 7.8 ± 0.9 (c), nM (1S*,2R*,3R*)-ethyl 2-methyl-3-(2,3,6-tribromo-4,5-dimethoxyphenyl)cyclopropanecarboxylate [46]
7.2.25 43.1 ± 1.7 (a), nM (1R*,2R*,3R*)-2-(2-Bromo-4,5-dimethoxyphenyl)-3-methylcyclopropane-1-carboxylic acid [46]
Notes: a, hCA II; b, hCA IV; c, hCA I; d, hCA VI. Values are for Ki, unless labeled as IC50.
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2.7.3. Glucose 6-Phosphate Dehydrogenase (G6PD) Inhibitory Activity
G6PD is a key enzyme in the pentose phosphate pathway, and a potential target for the treatment
of obesity and cancer. Some BPs exhibited inhibitory activity on G6PD. For example, BPs 7.3.1–7.3.3
(Scheme 9) isolated from three rhodomelaceae algae species (Laurencia nipponica, Polysiphonia morrowii,
and Odonthalia corymbifera) had inhibitory effects on G6PD with IC50 values ranged from 0.85 ± 0.1 to
76.6 ± 0.1 µM (Table 7). Among them, BP 7.3.3 (also 1.1, 2.8, and 4.7) had the strongest inhibitory effect
on G6PD with an IC50 value of 0.85 ± 0.1 µM (Table 7). Primary SAR studies found that dimer BPs
exhibited stronger inhibitory effects than the monomers, and as the substitution of bromine atoms
increased, the inhibitory effects also increased [117]. The 7.3.4 (Scheme 9) was a novel BP isolated from
the algae Odonthalia corymbifera, Neorhodomela aculeata, and Symphyocladia latiuscula. This compound
had an inhibition activity on G6PD of prokaryotic Leuconostoc mesenteroides, with an IC50 value of
321 ± 18 µM (Table 7). However, the inhibitory effect of BP 7.3.4 on G6PD of another eukaryotic
Saccharomyces cerevisiae was not obvious. This specificity was presumed to be due to the difference of the
recognition site of the hydrophobic alkyl group on the side chain of the compound [118]. In addition,
other BPs were used in this study to investigate the effect of compound structure on inhibition of G6PD
derived from prokaryotes and eukaryotes. Studies found that 7.3.5 (also 2.3, 6.3, and 7.1.2) and 7.3.6
(Scheme 9) had a stronger inhibitory effect on G6PD of prokaryotic Leuconostoc mesenteroides, with IC50
values of 0.97 ± 0.1 and 0.85 ± 0.1 µM, respectively (Table 7), but BPs 7.3.7, 7.3.8, and 7.3.2 (Scheme 9)
had stronger inhibitory effects on G6PD of eukaryotic Saccharomyces cerevisiae with IC50 values of
0.47 ± 0.03, 0.53 ± 0.18, and 0.39 ± 0.23 µM, respectively (Table 7). It can be seen that the dibenzyl
ether type symmetric BP dimers have strong inhibitory effects on G6PD of prokaryotic Leuconostoc
mesenteroides, while the diarylmethane type symmetric BP dimers have strong inhibitory effects on
G6PD of eukaryotic Saccharomyces cerevisiae [118].Mar. Drugs 2020, 18, x FOR PEER REVIEW 25 of 38 
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Table 7. IC50 of G6PD inhibitory activity and names of compounds in Scheme 9.
No. IC50 (µM) Names
7.3.1 76.6 ± 0.1 (a) 3,5-dibromo-4-hydroxybenzaldehyde [117]
7.3.2 4.01 ± 0.3 (a), 3,4-dibromo-5-(2-bromo-3,4-dihydroxy-6-(hydroxymethyl)benzyl)benzene-1,2-diol [117]
7.3.3 0.85 ± 0.1 (a) Bis(2,3-dibromo-4,5-dihydroxybenzyl)ether [117]
7.3.4 321 ± 18 (a) 3,4-dibromo-5-(butoxymethyl)benzene-1,2-diol [118]
7.3.5 0.97 ± 0.1 (a) Bis-(2,3,6-tribromo-4,5-dihydroxybenzyl methyl ether) [118]
7.3.6 0.85 ± 0.1 (a) 5,5’-(oxybis(methylene))bis(3,4-dibromobenzene-1,2-diol) [118]
7.3.7 0.47 ± 0.03 (a) 5,5’-methylenebis(3,4-dibromobenzene-1,2-diol) [118]
7.3.8 0.53 ± 0.18 (a) 3,4-dibromo- -(2-bromo-3,4-dihydroxy-6-( ethoxymethyl)benzyl)benzene-1,2-diol [118]
Notes: a, Leuconostoc mesenteroides G6PD; b, Saccharomyces cerevisiae G6PD.
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2.7.4. Possible Toxicological Effects of BPs
Not all the natural BPs and their derivatives show beneficial health effects. Some BPs are suspected
to have negative impacts on human and animal health as well as on the environment. In addition to
the toxic effects that we reviewed in 2011 [38], some novel negative effects of BPs have been reported.
For example, seven hydroxylated polybrominated diphenyl ethers (OH-PBDEs, 7.4.1–7; Scheme 10)
and four methoxylated polybrominated diphenyl ethers (MeO-PBDEs, 7.4.8–11; Scheme 10) were
discovered in macroalgae and blue mussels [28]. According to the reports, PBDEs had the potential for
endocrine disorders, neurological toxicities, and genotoxicity [119,120]. Moreover, they also caused
environmental pollution and were difficult to degrade [121]. Fortunately, PBDEs could be degraded by
UV irradiation [122].
Three BPs 7.4.12–14 (Scheme 10) have been reported to affect the activity of paraoxona (arylesterase,
EC 3.1.8.1, PON1) [40]. PON1 is an important enzyme preventing atherosclerosis. Moreover,
it also has anti-atherogenic and antioxidant effects, and hydrolyzes many chemical agents [40].
Compounds 7.4.12–14 exhibited moderate inhibition of PON1 with IC50 values of 0.832, 1.11,
and 0.701 mM, respectively, and the inhibition of PON1 led to the increase of oxidative stress and
oxidized low density lipoproteins, which enhances the risk of cardiovascular disease [40]. Therefore,
the possible toxicity of BPs for all life forms and environment should be kept in mind.
UDP-glucuronosyltransferases (UGTs), an important member of phase II drug-metabolizing
enzymes, have been demonstrated to play an important role in the elimination of various substances
through conjugation of lipophilic substances with glucuronic acids. UGTs-catalyzed metabolic reaction
can decrease the activity and increase the water solubility of toxic compounds. Therefore, inhibition of
these UGTs will slow down the excretion of xenobiotics [123]. A recent study found that BPs 7.4.15–20
(Scheme 10) had inhibitory effects on UGTs, with UGT1A7 being the most sensitive UGT isoform.
BP 7.4.15 has shown in vitro inhibitory effects on UGT1A3, UGT1A7, and UGT2B7, with Ki values of
2.85, 3.99, and 31.00 µM, respectively [124]. The SAR of BPs showed that the position and number
of bromine atom played a vital role for the inhibition activity. In addition, the hydrophobic contacts
of BPs with the active cavity of UGTs also contributed to the UGTs inhibition. The in vitro-in vivo
extrapolation also demonstrated that BP 7.4.15 had moderate inhibitory activities in vivo on UGT1A3
and UGT1A7 [124]. Therefore, this BP may have a negative effect on the human body by targeting
UTGs and affecting the pharmacokinetics of other agents.
Mar. Drugs 2020, 18, x FOR PEER REVIEW 26 of 38 
 
UDP-glucuronosyltransferases (UGTs), an important member of phase II drug-metabolizing 
enzymes, have been demonstrated to play an important role in the elimination of various substances 
through conjugation of lipophilic substances with glucuronic acids. UGTs-catalyzed metabolic 
reaction can decrease the activity and increase the water solubility of toxic compounds. Therefore, 
inhibition of these UGTs will slow down the excretion of xenobiotics [123]. A recent study found that 
BPs 7.4.15–20 (Schem  10) had inhibitory effects on UGTs, with UGT1A7 being the most sensitive 
UGT isoform. BP 7.4.15 has shown in vitro inhibitory effects on UGT1A3, UGT1A7, and UGT2B7, 
with Ki values of 2.85, 3.99, and 31.00 µM, respectively [124]. The SAR of BPs showed that the position 
and number of bromine atom played a vital role for the inhibition activity. In addition, the 
hydrophobic contacts of BPs with the active cavity of UGTs lso contri uted to the UGTs inhibition. 
The in vitro–in vivo extrapolation also demonstrated that BP 7.4.15 had moderate inhibitory activities 
in vivo on UGT1A3 and UGT1A7 [124]. Therefore, this BP may have a negative effect on the human 
body by targeting UTGs and affecting the pharmacokinetics of other agents. 
 
Scheme 10. BPs with possible toxicological effects. 
3. Mode of Interaction between the BP Compounds and Targets 
Understanding the mode of interaction is important in order to modify natural BPs into 
something even more efficient. BPs can interact in typical three ways: hydrogen bonding, halogen 
bonding, π–π interactions involving aromatic rings, and hydrophobic interactions. In the latter case, 
the polysubstituted benzene ring, OH, and/or Br substituents will act as an electron deficient entity. 
Hydrogen bonding is well understood by now [125]. The importance of halogen bonding in the 
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3. Mode of Interaction between the BP Compounds and Targets
Understanding the mode of interaction is important in order to modify natural BPs into
something even more efficient. BPs can interact in typical three ways: hydrogen bonding, halogen
bonding, π–π interactions involving aromatic rings, and hydrophobic interactions. In the latter case,
the polysubstituted benzene ring, OH, and/or Br substituents will act as an electron deficient entity.
Hydrogen bonding is well understood by now [125]. The importance of halogen bonding in the
interaction of small molecules with proteins has become more and more clear. The halogen is typically
interacting with an electron-rich site (Lewis base), usually in a linear fashion. The donor and the
acceptor should be within the sum of the van der Waals radii. The acceptor is typically a C=O
group from the protein backbone, but another oxygen is also at play, and so are N- and S-containing
groups. Interaction with π-systems is also possible, whereas interactions with C-H bonds are secondary
interactions [126].
Docking of BP 2.8 (also 1.1, 4.7, and 7.3.3) into α-glucosidase has been studied (Figure 1).
The docking results indicated the interaction between BP 2.8 and α-glucosidase was driven by both
hydrophobic forces and hydrogen bonds. The docked BP 2.8 molecule was completely buried in the
α-glucosidase binding pocket with part of the molecule reaching the catalytic center and overlapping
with the position of glucose, and the rest of the molecule extending toward the protein surface [71].
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Figure 1. Molecular docking of 2.8 to the active site of α-glucosidase [71].
Docking of BP 2.1 (also 6.1 and 7.1.1), BP 2.2 (also 6.2), and BP 2.3 (also 6.3, 7.1.2, and 7.3.5) into
AChE has bee studied [9]. From Figure 2, it can be seen that m st of the interact ons involving
bromine occur with aromatics, Trp84 and Phe330. For 2.2, an interaction between bromine is to a C=O,
again to Phe330, and to the OH bond of Ser122. For 2.3, an interaction is seen between bromine and
a NH of Gly11, and again to the aromatic ring of Trp84. Strangely enough, the interactions with the
aromatic rings are shown at the rims of the rings, whereas other studies show binding to the center [127].
Docking of 2.1–2.3 has also been done with BChE (Figure 3) and with BACE1 (Figure 4) [9].
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Figure 2. Molecular docking of 2.1 to the active site of Tetronarce californica AChE [9]. (https://pubs.acs.
org/doi/10.1021/acsomega.9b01557) Reproduced with permission from the American Chemical Society.
Readers who wish to obtain further permissions related to the material excerpted should be directed to
the ACS.
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Docking of BP 2.1 (also 6.1 and 7.1.1), BP 2.2 (also 6.2), and BP 2.3 (also 6.3, 7.1.2, and 7.3.5) has 
also been done with the PTP1B enzyme. For 2.1, the bromine atoms were involved in interactions 
with Thr263, Val184, Gln266, Gly183, Arg221, Phe1823, Lys116, and Trp176 [64]. An inspection of the 
graphics revealed major interactions to a side-chain nitrogen of Arg221 and to the OH group of 
Thr263, whereas the remaining interactions are to CH bonds. Docking of 2.1–2.3 has also been done 
to the oxy-form of Agaricus bisporus tyrosinase [113]. The interactions are not specified. 
In another docking study, (2S)-2-amino-3-(3-bromo-5-hydroxy-4-methoxyphenyl) propanoic 
acid was docked to Porphyromonas gingivalis Peptidyl. In this case, the bromine points toward a lysine. 
Other docking experiments bind 2-N-(2,3-dibromo-4,5-dihydroxybenzyl)-9-β-α-
ribofuranosyloxyguanosine with Rgp or HgA [9]. In those two cases, the bromine does not seem to 
play a role in the binding. The binding of 3.24 to Keap1-Kelch was studied [42]. One bromine is 
pointing toward the hydrophobic region, but the bromines do not seem to play a major role in 
binding. The authors of that study found that the alkyl substituents are much more important, which 
Figure 3. Molecular docking of 2.1 t the active site of human BChE [9]. (https://pubs.acs.org/doi/10.
1021/acsomega.9b01557) Reproduced with permission from the American Che ical Society. Readers
who wish to obtain further permissions related to the material excerpted should be directed to the ACS.
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Figure 4. Molecular docking of 2.1 to the active site of human BACE1 [9]. (https://pubs.acs.org/doi/10.
1021/acsomega.9b01557) Reproduced with permission from the American Chemical Society. Readers
who wish to obtain further permissions related to the material excerpted should be directed to the ACS.
Docking of BP 2.1 (also 6.1 and 7.1.1), BP 2.2 (also 6.2), and BP 2.3 (also 6.3, 7.1.2, and 7.3.5) has
also been done with the PTP1B enzyme. For 2.1, the bromine atoms were involved in interactions
with Thr263, Val184, Gln266, Gly183, Arg221, Phe1823, Lys116, and Trp176 [64]. An inspection of the
graphics revealed major interactions to a side-chain nitrogen of Arg221 and to the OH group of Thr263,
whereas the remaining interactions are to CH bonds. Docking of 2.1–2.3 has also been done to the
oxy-form of Agaricus bisporus tyrosinase [113]. The interactions are not specified.
In another docking study, (2S)-2-amino-3-(3-bromo-5-hydroxy-4-methoxyphenyl) propanoic
acid was docked to Porphyromonas gingivalis Peptidyl. In this case, the bromine points
toward a lysine. Other docking experiments bind 2-N-(2,3-dibromo-4,5-dihydroxybenzyl)-9
-β-α-ribofuranosyloxyguanosine with Rgp or HgA [9]. In those two cases, the bromine does not seem
to play a role in the binding. The binding of 3.24 to Keap1-Kelch was studied [42]. One bromine is
pointing toward the hydrophobic region, but the bromines do not seem to play a major role in binding.
The authors of that study found that the alkyl substituents are much more important, which is not
surprising as the BP is only a minor part of the molecule. Docking of 2.11 has also been done,
but with no emphasis on bromine [76]. It would be interesting with a more detailed analysis of the
docking experiments following the principles mentioned above. SAR experiments showed in two
Mar. Drugs 2020, 18, 411 23 of 32
cases increased binding with an increasing number of bromines [73,117], whereas no effect was found
in a third study [46].
Docking of BP 2.13 into PTP1B has been studied and revealed that hydrogen bonding and
hydrophobic interactions are the major action modes between BP 2.13 and PTP1B. As can be seen
from Figure 5, the ethoxy group of BP 2.13 at the para-position of the benzene ring can occupy the
hydrophobic cavity near Ala27, which forms selective inhibition of PTP1B. Moreover, the ethoxy group
can form hydrogen bond with Arg254 in PTP1B [78].
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BP 6.1 (also 2.1 and 7.1.1), BP 6.2 (also 2.2), and BP 6.3 (also 2.3, 7.1.2, and 7.3.5) docked to D3R 
ligands indicated that Asp110, Cys114, His349, and Phe345 are the most important residues, and 
hydrogen bonds are formed between the compound and these amino acid residues (Figure 7). 
Moreover, BPs 6.1–6.3 were also docked to D4R, and BP 6.3 showed the strongest combination ability 
to D4R. Phenolic hydroxyl groups in BP 6.3 can form various hydrogen bonds with Ser196, Asp115, 
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Docking of BP 6.1 (also 2.1 and 7.1.1), BP 6.2 (also 2.2), and BP 6.3 (also 2.3, 7.1.2, and 7.3.5) into
hMAO-A and dopamine D3/D4 receptor has been studied. BPs 6.1–6.3 c mpetitively binds to the
catalytic site of hMAO-A. As can be seen from Figure 6, phenolic hydr xyl groups in BP 6.1 can
form hydrogen bonds with Tyr444, FAD600, Asn181, and Ile207. In addition, methoxyl and phenolic
xyl groups in BP 6.2 can form hydrogen bonds with Gln215 and FAD600, while phenolic hydroxyl
groups in BP 6.3 ca form hydrogen bonds with Lys363, Me 300, and Asp359 [109].
BP 6.1 (also 2.1 and 7.1.1), BP 6.2 (also 2.2), and BP 6.3 (also 2. , 7.1.2, and 7.3.5) docked to
D3R ligands indicated that Asp110, Cys114, His349, and Phe345 are the most important residues,
and hydrogen bonds are formed between the compound and these a ino acid esidu (Figure 7).
Moreover, BPs 6.1–6.3 were also docked o D4R, and BP 6.3 showed the strongest combination ability
to D4R. Phenolic hydroxyl groups in BP 6.3 can form various hydrog n b ds with Ser196, Asp115,
Val193, and Ser197 residues (Figure 8) [109].
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methanesulfonyl moieties of BP 6.15 are surrounded by hydrophobic residues in the AChE 
catalytically active site, including Tyr72, Tyr124, Trp286, Leu289, Val294, Phe295, Phe297, Tyr337, 
Phe338, and Tyr341. As shown in Figure 10, the 3,4-dibromo benzene-1,2-diol portion of BP 6.14 is 
surrounded by hydrophilic residues Glu197 and Ser198 and hydrophobic residue Trp82, but the 
CH3SO2 portion is surrounded by the hydrophobic residues Met437 and Tyr440 of BChE [111]. 
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4. Conclusions 
In the last decade, intensive efforts and great progress have been made in the isolation, synthesis, 
and novel biological activities by screening of BPs. The marine BPs and the synthetic derivatives 
continue to enlarge the chemical library and improve the opportunity to discover new agents, while 
interesting novel BPs will still be found, and derivatives will be designed and synthesized in the 
future. The pharmacology activities of BPs and their derivatives are mainly focused on anticancer, 
antidiabetic, anti-obesity, antiradical, antimicrobial, anti-inflammatory, anti-AD, anti-PD, and 
enzyme inhibitory activities. SAR studies on the natural and synthetic BPs reveal that some core 
structure or substituents may play a critical role for the biological activity. However, it has been 
proved difficult to identify a selective, safe, and effective new drug from these marine-derived BPs. 
Due to the limited amount of natural BPs in marine algae, immediate in vivo investigations may 
hinder the research and development of BP-based drugs. However, the number of semisynthetic and 
synthetic brominated compounds has been increasing, and more in vivo trials have been recently 
conducted than were conducted ten years ago. In addition, some mechanisms underlying the BPs’ 
distribution and mechanisms of their targets are being illustrated, which will enhance the structure 
optimization of the natural BPs. The discovery of natural marine BPs with novel skeletons, the 
screening of their bioactivities, their structure modification via synthetic and semisynthetic routes, 
and the optimization of pharmacokinetic and pharmacodynamics parameters continue to be crucial 
subjects in the future investigations of this area in order to provide new lead compounds for drug 
development. 
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In the last decade, intensive efforts and great progress have been made in the isolation, synthesis,
and novel biological activities by screening of BPs. The marine BPs and the synthetic derivatives
continue to enlarge the chemical library and improve the opportunity to discover new agents,
while interesting novel BPs will still be found, and derivatives will be designed and synthesized in the
future. The pharmacology activities of BPs and their derivatives are mainly focused on anticancer,
antidiabetic, anti-obesity, antiradical, antimicrobial, anti-inflammatory, anti-AD, anti-PD, and enzyme
inhibitory activities. SAR studies on the natural and synthetic BPs reveal that some core structure or
substituen s may play a cri ical role for the biological activity. However, it has been proved difficult
to identify a selective, safe, and effective new rug from these marine-derived BPs. Due to the
limited amount of natural BPs in marine algae, immediate in vivo investigations may hinder the
research and development of BP-based drugs. However, the number of semisynthetic and synthetic
brominated compounds has been increasing, and more in vivo trials have been recently conducted
than were conducted ten years ago. In addition, some mechanisms underlying the BPs’ distribution
and mechanisms of their targets are being illustrated, which will enhance the structure optimization
of the natural BPs. The discovery of natural marine BPs with novel skeletons, the screening of their
bioactivities, their structure modificatio via synthetic and semisynthetic routes, and the optimization
of pharma ok etic and pharmacodynamics par meters continue to be crucial subjects in the future
investigations of this area in order to provide new lead compounds for drug development.
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Abbreviatio s
A549: human lung adenocarcinoma epithelial cell line; ABTS, 2,2′-azinobis (3-ethylbenzothiazoline-6-sulfonic
acid) diammonium salt; AChE, acetylcholinesterase; AD, Alzheimer’s disease; ADME, absorption, distribution,
metabolism, and excretion; APN, acute pyelonephritis; AR, aldose reductase; BACE1, β-site amyloid precursor
protein cleaving enzyme 1; BChE, butyrylcholinesterase; Bel7402, human hepatoma cell line; B16F10, malignant
melanoma cell line; BHT, butylated hydroxytoluene; BPs, bromophenols; CA, carbonic anhydrase; Caco2,
human clonal colon adenocarcinoma cell line; C2C12, mouse myoblast cell line; ChEs, cholinesterases; CPT-1B,
carnitine palmitoyl transferase 1B; 95D, human highly metastatic lung cancer cell line; D3/D4R, dopamine D3/D4
receptor; DPPH, 1,1-diphenyl-2-picryl hydrazyl; ERK, extracellular signal-regulated kinase; FABP3, fatty acid
binding protein 3; FAK, focal adhesion kinase; G6PD, glucose 6-phosphate dehydrogenase; GSH, glutathione;
GSK-3β, glycogen synthase kinase-3β; HbA1c, hemoglobin A1c; HCC-1937, human breast cancer cell line; HCT-8,
human colorectal carcinoma cell line; HCT-116, human colorectal carcinoma cell line; HeLa, human cervical
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carcinoma cell line; HepG2, human hepatocellular carcinoma cell line; HgA, hemagglutinin A; hMAO-A, human
monoamine oxidase-A; HUVEC, human umbilical vein endothelial cell line; IgE, immunoglobulin E; IHNV,
infectious hematopoietic necrosis virus; IKK, iκB kinase; IL-6, interleukin-6; IL-1β, interleukin-1β; IPNV, infectious
pancreatic necrosis virus; K562, human myelogenous leukemia cell line; Keap1, kelch-like ECH-associated protein
1; MAPK, mitogen-activated protein kinase; MCF-7, human breast adenocarcinoma cell line; MDB-MB-231,
human breast cancer cell line; MDR-TB, multidrug resistant-tuberculosis; MIC, minimum inhibitory concentration;
mTOR, mammalian target of rapamycin; NCI-H460, human large cell lung cancer cell line; NF-κB, nuclear
factor kappa-light-chain-enhancer of activated B cells; Nrf2, nuclear factor erythroid 2-related factor 2; PBDEs,
polybrominated diphenyl ethers; PD, Parkinson’s disease; PGE2, prostaglandin E2; PON1, paraoxonase-1; PI3K,
phosphoinositide 3 kinase; PTPs, protein tyrosine phosphatases; PTP1B, tyrosine phosphatase 1B; RAW 264.7,
leukemia cells in mouse macrophage; RBPs, RNA-binding proteins; Rgp, gingipain R; RKO, human colon
adenocarcinoma cell line; ROS, reactive oxygen species; SAR, structure activity relationships; SK-OV-3, human
ovarian cancer cell line; SMMC-7721, human hepatocellular carcinoma cell line; STAT1, signal transducer and
activator of transcription 1; TEAC, trolox equivalent antioxidant capacity; TNF-α, tumor necrosis factor-α; U87,
human glioma cell line; UGTs, UDP-glucuronosyltransferases; UVB, ultraviolet B; VEGF, vascular endothelial
growth factor; Vero, African green monkeys kidney cells.
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